Overview

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

Status:
Active, not recruiting
Trial end date:
2022-10-18
Target enrollment:
Participant gender:
Summary
The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.